Other

Siemens Healthcare Diagnostics Gmbh

Siemens Aktiengesellschaft

Siemens Healthcare Diagnostics Products Gmbh

Biontech Diagnostics Gmbh

Stratifyer Molecular Pathology Gmbh

Wirtz, Ralph Markus

Wirtz, Ralph

Ralph Markus Wirtz

Sebastian Schmidt

Arne Hengerer

Guido Hennig

Udo Stropp

Christian Geppert

Ralf Kronenwett

Kerstin Bohmann

Susanne Schmolke

Marc Munnes

Karsten Weber

Christoph Kneip

Sven Meyburg

Wolfgang Michael Bruckl

Robert P Thiel

Birge Schopper

Mathias Gehrmann

Axel Wein

Manuela Averdick

Wolfgang BRÜCKL

George Fountzilas

Wolfgang Michael Brückl

The present invention relates to an in vitro method of identifying a molecular subtype of a tumor in a cancer patient and to a method of stratifying a cancer patient for tumor treatment. The present invention further relates to kits that are useful for identifying a molecular subtype of a tumor in a cancer patient.

Methods and kits for the molecular subtyping of tumors

The present invention is related to a method for analyzing a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of three genes of interest, said genes being correlated with the Estrogen receptor (ESR) status in the sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c); and treating based on said outcome.

Method for predicting therapy responsiveness in basal like tumors

The present invention relates to matrix materials suitable for use in purifying and/or isolating nucleic acids from a biological sample, which matrix comprises a surface comprising at least one element selected from the group consisting of Germanium, Tin and/or Lead, or at least one salt thereof, and methods related therewith.

Matrix and method for purifying and/or isolating nucleic acids

The present invention is related to a method of classifying a sample of a patient who suffers from or being at risk of developing cancer, said method comprising the steps of determining in said sample from said patient, on a non protein basis, the expression level of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor in said sample; comparing the one or more expression level(s) determined with one or more expression level(s) of one or more reference genes, and classifying the sample of said patient from the outcome of the comparison into one of at least two classifications.

Method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels

At least one embodiment of the invention relates to bone marrow precursor cells or bone marrow cells of a patient, the cells labeled with at least one contrast agent suitable for an imaging method, for use in an imaging method for diagnosing a metastasizing cancer, wherein the local accumulation of the labeled precursor cells or bone marrow cells indicates the presence of a metastasizing tumor growth. At least one embodiment also relates to a method for imaging a metastasizing tumor tissue in a patient, wherein a) bone marrow precursor cells or bone marrow cells are extracted from a patient, b) these precursor cells or bone marrow cells are labeled with at least one contrast agent suitable for an imaging method, c) the precursor cells or bone marrow cells thus labeled are retransplanted or reinjected into the patient, and d) the presence of metastasizing tumor cells is depicted with an imaging method. At least one embodiment also relates a method for imaging a metastasizing tumor tissue, wherein a suitable imaging method is used to image bone marrow precursor cells and/or bone marrow cells that are accumulated in a metastasizing tumor tissue and labeled with at least one contrast agent suitable for an imaging method.

Tracking of bone marrow cells for metastasis screening

The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing cancer, preferably colorectal cancer, towards a given mode of treatment, the method including the steps of: a) obtaining a biological sample from the patient; b) determining the expression level of at least SPON-2, and optionally determining the expression level of SPON-1, in the sample; c) comparing the expression level or expression levels determined in (b) with one or several reference expression levels; and d) predicting therapeutic success for the given mode of treatment in the patient or implementing therapeutic regimen in the patient from the outcome of the comparison in step (c).

Method for predicting a clinical response of a patient suffering from or at risk of developing cancer towards a given mode of treatment

The present invention relates to an automatable method for the improved diagnosis of pathologically altered cells by simultaneously staining at least two different molecular markers, which exhibit a change in gene expression which is disease-associated, in a cell or constituent regions of a tissue sample by means of using combinations of antibodies and accrediting signal intensities.

Method for increasing clinical specificity when detecting tumors and their precursor stages by simultaneously measuring at least two different molecular markers

Growing community of inventors

Kö'ln, Germany

Ralph Markus Wirtz